Prospective one-year bone loss in treatment-naïve HIV+ men and women on single or multiple drug HIV therapies

Bone

Volumn 48, Issue 5, 2011, Pages 1133-1139

  Briot, K ^a   Kolta, S ^a   Flandre, P ^b   Boue F ^c   Ngo Van, P ^d   Cohen Codar, I ^d   Norton, M ^e   Delfraissy, J F ^f   Roux, C ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HÔPITAL ANTOINE BÉCLÈRE   (France)

^d Abbott   (France)

^e ABBOTT LABORATORIES   (United States)

^f BICÊTRE HOSPITAL   (France)

Author keywords

Antiretroviral therapy; Bone densitometry; Fracture; HIV; Osteoporosis

Indexed keywords

LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR;

ADULT; AGE; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OSTEOPOROSIS; PREDICTIVE VALUE;

ABSORPTIOMETRY, PHOTON; ANTI-HIV AGENTS; BONE DENSITY; BONE RESORPTION; DRUG THERAPY, COMBINATION; FEMALE; HIV SEROPOSITIVITY; HUMANS; MALE; PROSPECTIVE STUDIES; SEX CHARACTERISTICS; TIME FACTORS;

EID: 79954596937     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.01.015     Document Type: Article

References (44)

1. Palella F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
2. DHHS panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.
3. Lipsky J.J. Abnormal fat accumulation in patients with HIV-1 infection. Lancet 1998, 351:847-848.
4. Carr A., Samaras K., Burton S., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
5. Knobel H., Guelar A., Vallecillo G., Nogues X., Diez A. Osteopenia in HIV-infected patients: is it the disease or is it the treatment?. AIDS 2001, 15:807-808.
6. Huang J.S., Wilkie S.J., Sullivan M.P., Grinspoon S. Reduced bone density in androgen-deficient women with acquired immune deficiency syndrome wasting. J Clin Endocrinol Metab 2001, 86:3533-3539.
7. Dolan S.E., Huang J.S., Killilea K.M., Sullivan M.P., Aliabadi N., Grinspoon S. Reduced bone density in HIV-infected women. AIDS 2004, 18:475-483.
8. Cazanave C., Dupon M., Lavignolle-Aurillac V., et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 2008, 22:395-402.
9. Prior J., Burdge D., Maan E., et al. Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. Osteoporos Int 2007, 18:1345-1353.
10. Triant V.A., Brown T.T., Lee H., Grinspoon S.K. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008, 93:3499-3504.
11. Arnsten J.H., Freeman R., Howard A.A., Floris-Moore M., Lo Y., Klein R.S. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007, 21:617-623.
12. Dao C., Young B., Buchacz K., et al. Higher and increasing rates of fracture among hiv-infected persons in the HIV outpatient study compared to the general US population, 1994 to 2008. Oral Abstract 128, Session 37. 17th Conference on Retroviruses and Opportunistic Infections February 16-19, 2010, San Francisco, USA.
13. Collin F., Duval X., Le Moing V., et al. Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS 2009, 23:1021-1024.
14. Carr A., Miller J., Eisman J.A., Cooper D.A. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS 2001, 15:703-709.
15. Yin M., Dobkin J., Brudney K., et al. Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int 2005, 16:1345-1352.
16. Fausto A., Bongiovanni M., Cicconi P., et al. Potential predictive factors of osteoporosis in HIV-positive subjects. Bone 2006, 38:893-897.
17. Brown T.T., Qaqish R.B. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006, 20:2165-2174.
18. Jones S., Restrepo D., Kasowitz A., et al. Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int 2008, 19:913-918.
19. Tebas P., Powderly W.G., Claxton S., et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000, 14:F63-F67.
20. Grund B., Peng G., Gibert C.L., et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009, 23:1519-1529.
21. Bolland M.J., Grey A.B., Gamble G.D., Reid I.R. Low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab 2007, 92:4522-4528.
22. Delfraissy J.F., Flandre P., Delaugerre C., et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 2008, 22:385-393.
23. Delfraissy J.F., Flandre P., NgoVan P., et al. One-year fat tissue distribution changes in antiretroviral naive HIV-infected patients treated with lopinavir/ritonavir (LPV/r) monotherapy versus LPV/r with zidovudine/lamivudine (AZT/3TC) in the MONARK trial. Poster presentation WEPEB118LB. 4th IAS conference on HIV pathogenesis, treatment and prevention July 22-25, 2007, Sydney, Australia.
24. Yeni P.G., Hammer S.M., Hirsch M.S., et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA panel. JAMA 2004, 292:251-265.
25. Hammer S.M., Eron J.J., Reiss P., et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008, 300:555-570.
26. Genant H.K., Grampp S., Glüer C.C., et al. Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res 1994, 9:1503-1514.
27. Ravaud P., Reny J.L., Giraudeau B., Porcher R., Dougados M., Roux C. Individual smallest detectable difference in bone mineral density measurements. J Bone Miner Res 1999, 14:1449-1456.
28. Pan G., Yang Z., Ballinger S.W., McDonald J.M. Pathogenesis of osteopenia/osteoporosis induced by highly active anti-retroviral therapy for AIDS. Ann NY Acad Sci 2006, 1068:297-308.
29. Peyriere H., Reynes J., Rouanet I., et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004, 35:269-273.
30. Gallant J.E., Staszewski S., Pozniak A.L., et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292:191-201.
31. Wirz S., Rubeli S., Christen A., et al. Renal phosphate wasting and increased boneturnover in TDF-treated patients are not mediated by low 25(oh) vitamin d or hyperparathyroidism. Poster presentation 749. 17th conference on retroviruses and opportunistic infections February 16-19, 2010, San Francisco, USA.
32. Cazanave C., Lawson-Ayayi S., Barthe N., et al. Changes in bone mineral density: two-years follow-up of the ANRS CO3 Aquitaine cohort. Poster presentation 193. 17th conference on retroviruses and opportunistic infections February 16-19, 2010, San Francisco, USA.
33. Delpierre C., Bonnet E., Marion-Latard F., et al. Impact of HIV infection on total body composition in treatment-naive men evaluated by dual-energy X-ray absorptiometry comparison of 90 untreated HIV-infected men to 241 controls. J Clin Densitom 2007, 10:376-380.
34. Dolan S.E., Kanter J.R., Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 2006, 91:2938-2945.
35. Nolan D., Upton R., McKinnon E., et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001, 15:1275-1280.
36. Jacobson D.L., Spiegelman D., Knox T.K., Wilson I.B. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr 2008, 49:298-308.
37. Mondy K., Yarasheski K., Powderly W.G., et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003, 36:482-490.
38. Dube M.P., Qian D., Edmondson-Melancon H., et al. Prospective, intensive study of metabolic changes associated with 48weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis 2002, 35:475-481.
39. Mallon P.W., Miller J., Cooper D.A., Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003, 17:971-979.
40. van Vonderen M.G., Lips P., van Agtmael M.A., et al. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 2009, 23:1367-1376.
41. Rivas P., Gorgolas M., Garcia-Delgado R., Diaz-Curiel M., Goyenechea A., Fernandez-Guerrero M.L. Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir. HIV Med 2008, 9:89-95.
42. Duvivier C., Kolta S., Assoumou L., et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009, 23:817-824.
43. Brown T.T., McComsey G.A., King M.S., Qaqish R.B., Bernstein B.M., da Silva B.A. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009, 51:554-561.
44. Amiel C., Ostertag A., Slama L., et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 2004, 19:402-409.